Related Experiment Video
Updated: Jun 9, 2026
11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report
Joan Manel Gasent Blesa1, Vicente Alberola Candel
1Department of Medical Oncology, Hospital de Dènia, Marina Salud, Dénia, Spain.
Case Reports in Oncology
|August 27, 2010
Summary
Metastatic prostate cancer requires new treatments. Fulvestrant acetate showed promise by controlling prostate-specific antigen (PSA) levels in a patient with advanced, hormone-resistant prostate cancer.
Area of Science:
- Oncology
- Endocrinology
Background:
- Metastatic prostate cancer is typically incurable, progressing to androgen-independent growth after hormone therapy.
- Chemotherapy is often challenging in elderly or fragile patients, necessitating novel therapeutic strategies.
- Preclinical studies suggest estrogen receptor (ER) signaling plays a role in prostate cancer progression.
Observation:
- This study reports on a patient with metastatic prostate cancer who experienced prostate-specific antigen (PSA) control.
- The patient was treated with fulvestrant acetate, a selective estrogen receptor degrader.
Findings:
- This represents the first published evidence of PSA control in metastatic prostate cancer using fulvestrant acetate.
- Fulvestrant acetate demonstrated efficacy in managing PSA levels in this specific patient case.
Implications:
- These findings suggest a potential therapeutic role for estrogen receptor (ER) signaling inhibitors like fulvestrant acetate in advanced prostate cancer.
- Further research into ER-targeted therapies could offer new treatment avenues for patients with hormone-refractory metastatic prostate cancer.
